SkyAI, Inc.
SkyAI, Inc. is a U.S.-based medical device company focused on syringe products and related drug-delivery systems. Its business includes the marketing and distribution of disposable and prefillable syringes, with operations tied to both domestic and international healthcare markets.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2022–2025
Liiketoiminta
Osuus liikevaihdostaSingle-use syringe products marketed for clinical and healthcare use.
Syringe platforms designed for drug-delivery and pharmaceutical applications.
Named syringe product lines used in the company's commercial offering.
Sales of existing inventory and third-party medical products through distribution channels.
Asiakkaat
The company sells to healthcare companies, distributors, hospitals, clinics, healthcare providers, and medical supply organizations. It also targets U.S. and foreign governments for syringe and related medical product procurement. Customer demand is driven by the need for reliable, compliant, commercially available syringe supply.
Buy syringe inventory and product lines for onward distribution into healthcare channels.
Purchase syringes for direct clinical use and routine patient care.
Source syringe products and drug-delivery systems for commercial supply arrangements.
Procure syringe products for public health, medical stockpiles, or institutional use.
Buy and distribute syringe products to healthcare providers and institutions.
Strategia
The company is focused on commercializing and distributing syringe products while building supply relationships with healthcare customers and distributors. It is also using its Hungarian facility and inventory base to support commercial quantities and order fulfillment. Beyond medical devices, it has added a digital asset treasury strategy centered on SOL and is exploring additional investments and acquisitions.
Revenue depends on converting product development and inventory into repeat customer orders.
Commercial supply requires reliable production and delivery capability.
Representing third-party products can extend the customer base and reduce reliance on a narrow product set.
The SOL treasury is intended to provide an additional reserve and potential funding source.
Maantiede
The company is headquartered in the United States and maintains a corporate office in Melville, New York. It also operates through a Hungarian manufacturing facility and markets products in both domestic and international markets, including Europe. Geography matters because manufacturing capacity, regulatory approvals, and customer access are all tied to where products are produced and sold.
Riskit
The business depends on successful commercialization of syringe products, customer acceptance, and uninterrupted manufacturing or distribution capacity. It also faces regulatory, inventory, and execution risk because medical devices require quality compliance and demand can be lumpy across customers and geographies. The added digital asset treasury strategy introduces market, custody, and valuation risk that is separate from the core medical device business.
- Commercialization and demand riskVaikutus: KorkeaTodennäköisyys: Matala
Revenue depends on converting syringe products into repeat orders from healthcare buyers and distributors.
Kohdistuu: Disposable and prefillable syringe sales
- Regulatory and quality compliance riskVaikutus: KorkeaTodennäköisyys: Matala
Medical devices must meet FDA and comparable international standards, and failures can block sales or trigger remediation.
Kohdistuu: U.S. and foreign medical device distribution
- Digital asset market riskVaikutus: Korkea
SOL holdings and staking revenue expose the company to price volatility, custody, and transaction risk.
Kohdistuu: Treasury reserve and staking activities
- Inventory reserve and obsolescence riskVaikutus: Keskitaso
The company carries syringe inventory, and slow sales can require write-downs or reserves.
Kohdistuu: Existing syringe inventory
- Manufacturing concentration riskVaikutus: Keskitaso
A key facility in Hungary supports production and testing, so disruptions could affect supply.
Kohdistuu: Hungarian operations
- Advisor and related-party governance riskVaikutus: MatalaTodennäköisyys: Matala
Non-arm's-length arrangements can produce less favorable commercial terms.
Kohdistuu: Consultant and strategic advisor relationships
Kirjanpito
Harkinnanvaraiset erätProduct revenue is tied to shipment and supply agreement execution, so timing affects quarterly comparability.
Vaikutus: Reported sales may be uneven as orders ramp
The company holds syringe inventory and may need reserves if realizable value falls below cost.
Vaikutus: Gross margin and asset values can be reduced
Manufacturing and facility assets must be tested if strategy or utilization changes.
Vaikutus: Non-cash charges can materially affect earnings
Liability-classified instruments are remeasured and can create volatility in non-operating results.
Vaikutus: Large gains or losses may not reflect core operations
SOL holdings and staking activity introduce valuation and transaction accounting complexity.
Vaikutus: Balance sheet and income statement volatility
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Skye Bioscience, Inc.
SKYE · Pharmaceutical Preparations
Skytech Orion Global Corp.
SKTG · Services-Prepackaged Software
Meihua International Medical Technologies Co., Ltd.
MHUAF · Surgical & Medical Instruments & Apparatus
Spectral AI, Inc.
MDAIW · Surgical & Medical Instruments & Apparatus
Zai Lab Ltd
ZLAB · Pharmaceutical Preparations
Zai Lab Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for oncology, immunology, neuroscience, and infectious diseases.
KORU Medical Systems, Inc.
KRMD · Surgical & Medical Instruments & Apparatus
KORU Medical Systems develops, manufactures, and commercializes portable large-volume subcutaneous infusion solutions used to deliver drugs under the FREEDOM Infusion System brand.
Päivitetty: 24.9.2026